- Home
- ALL vs EW Comparison
ALL vs EW Comparison
Compare ALL & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALL | EW |
|---|---|---|
| Founded | 1931 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.0B | 49.5B |
| IPO Year | 1993 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALL | EW |
|---|---|---|
| Price | $193.10 | $84.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $225.07 | $96.79 |
| AVG Volume (30 Days) | 1.7M | ★ 3.2M |
| Earning Date | 02-04-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ 99.54 | N/A |
| EPS | ★ 30.82 | 2.33 |
| Revenue | ★ $66,846,000,000.00 | $5,883,800,000.00 |
| Revenue This Year | N/A | $14.35 |
| Revenue Next Year | $6.05 | $9.73 |
| P/E Ratio | ★ $6.28 | $36.60 |
| Revenue Growth | 7.07 | ★ 10.60 |
| 52 Week Low | $176.00 | $65.94 |
| 52 Week High | $215.89 | $87.89 |
Technical Indicators
Market Signals| Indicator | ALL | EW |
|---|---|---|
| Relative Strength Index (RSI) | 34.45 | 47.75 |
| Support Level | $191.13 | $82.82 |
| Resistance Level | $196.09 | $86.20 |
| Average True Range (ATR) | 5.07 | 1.92 |
| MACD | -1.33 | -0.08 |
| Stochastic Oscillator | 8.44 | 52.34 |
Price Performance
Historical ComparisonAbout ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.